Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ).
Fuso Pharmaceutical Industries, Ltd. announced that the Intellectual Property High Court partially upheld a patent infringement claim by Toray Industries, Inc. regarding their product, Nalfurafine Hydrochloride OD Tablets. The court ordered Fuso to pay damages, impacting their financial results for the fiscal year ending March 2025. Fuso plans to appeal the decision to the Supreme Court, although their financial forecast for the fiscal year ending March 2026 remains unchanged.
More about Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries, Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of medical products, including oral antipruritic agents.
Average Trading Volume: 24,801
Technical Sentiment Signal: Buy
Current Market Cap: Yen19.61B
For a thorough assessment of 4538 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue